433 related articles for article (PubMed ID: 8525189)
1. [Erythropoietin and transfusions in patients with anemia of chronic renal failure origin : an update view].
Duclos J; Olea C; Aguirre H; Alvarez MC; Salgado MC
Rev Med Chil; 1995 Apr; 123(4):451-5. PubMed ID: 8525189
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
3. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
Pizzarelli F; David S; Sala P; Icardi A; Casani A
Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
[TBL] [Abstract][Full Text] [Related]
4. [Effect of recombinant human erythropoietin (rHu-EPO) on anemia and selected biochemical parameters in patients in the pre-dialysis period].
Sułowicz W; Drozdz M; Hanicki Z; Kraśniak A; Kuźniewski M
Przegl Lek; 1992; 49(1-2):50-3. PubMed ID: 1455007
[TBL] [Abstract][Full Text] [Related]
5. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643
[TBL] [Abstract][Full Text] [Related]
6. [Is it necessary to supplement with folic acid patients in chronic dialysis treated with erythropoietin?].
Duclos J; Sieberth HG; Mann H
Rev Med Chil; 1993 Jan; 121(1):30-5. PubMed ID: 8235161
[TBL] [Abstract][Full Text] [Related]
7. Treatment of anemia in renal transplantation: impact of a stricter application of hemoglobin targets.
Gentil MA; Pérez-Valdivia MA; González-Roncero FM; López-Mendoza M; Cabello V; Bernal G; Suñer M; Pereira P
Transplant Proc; 2008 Nov; 40(9):2916-8. PubMed ID: 19010146
[TBL] [Abstract][Full Text] [Related]
8. Treatment of the anemia with human recombinant erythropoietin in CAPD patients.
Miranda B; Selgas R; Riñon C; Fernandez-Zamorano A; Borrego F; Ortuño F; Lopez-Revuelta K; Torre A; Sanchez Sicilia L
Adv Perit Dial; 1990; 6():296-301. PubMed ID: 1982831
[TBL] [Abstract][Full Text] [Related]
9. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
10. [Human recombinant erythropoietin in the treatment of anemia in patients on long-term hemodialysis].
Boratyńska M; Szewczyk Z; Szepietowski T; Czyz W; Cybulski K; Bogucki J; Szczepański J
Przegl Lek; 1990; 47(11):741-5. PubMed ID: 2098840
[TBL] [Abstract][Full Text] [Related]
11. [Optimal therapy with erythropoietin (EPO) in patients with renal anemia on hemodialysis therapy].
Merta M; Sobotová D; Zahálková J; Bitterová Z; Jirka T; Knetl P; Kopenec J; Suchanová J; Vlasák J
Sb Lek; 2001; 102(1):41-52. PubMed ID: 11830918
[TBL] [Abstract][Full Text] [Related]
12. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
13. Can acidosis and hyperphosphataemia result in increased erythropoietin dosing in haemodialysis patients?
Diskin CJ; Stokes TJ; Dansby LM; Radcliff L; Carter TB
Nephrology (Carlton); 2006 Oct; 11(5):394-9. PubMed ID: 17014551
[TBL] [Abstract][Full Text] [Related]
14. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of anemia with recombinant human erythropoietin and the bone marrow response in uremic patients undergoing periodic hemodialysis].
García Martín F; Carrascosa Vallejo T; Martín Escobar E; Val Begueria J; Martín Hernández R; de Arriba G; Teno C; Salvatierra J
Rev Clin Esp; 1990 May; 186(9):419-22. PubMed ID: 2247677
[TBL] [Abstract][Full Text] [Related]
16. Infrequent dosing of subcutaneous erythropoietin for the treatment of anemia in patients on CAPD.
Bunke M; Bartlett DK; Brier ME; Golper TA
Adv Perit Dial; 1993; 9():331-5. PubMed ID: 8105957
[TBL] [Abstract][Full Text] [Related]
17. Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3.
Stefanovic V; Mitić-Zlatkovic M; Radivojevic J; Vlahovic P
Ren Fail; 2005; 27(3):283-8. PubMed ID: 15957544
[TBL] [Abstract][Full Text] [Related]
18. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
19. Effect of variability in anemia management on hemoglobin outcomes in ESRD.
Lacson E; Ofsthun N; Lazarus JM
Am J Kidney Dis; 2003 Jan; 41(1):111-24. PubMed ID: 12500228
[TBL] [Abstract][Full Text] [Related]
20. Human recombinant erythropoietin treatment in transfusion dependent anemic patients on maintenance hemodialysis.
Zehnder C; Blumberg A
Clin Nephrol; 1989 Feb; 31(2):55-9. PubMed ID: 2920469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
